share_log

Xenon Pharmaceuticals Q3 2024 GAAP EPS $(0.81), Inline

Benzinga ·  Nov 13 05:06

Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.81) per share which met the analyst consensus estimate.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment